# MEDROXYPROGESTERONE

**Class**  
Progestogen

**Presentation**  
**Tablet:** 5mg, 10mg, 100mg, 200mg  
**Vial:** 150mg/1mL

**Storage**  
Store at room temperature, below 25°C

**Dose**

**Contraception**
- **IM Injection:** 150mg every 12 weeks

**Endometriosis**
- **IM Injection:** 150 mg every 12 weeks
- **Oral:** 10 mg 3 times daily

**Heavy Menstrual Bleeding (anovulatory)**
- **Oral:** 5–10 mg daily in 1 or 2 doses for 10–14 days during assumed second half of cycle

**Secondary Amenorrhoea**
- **Oral: Without estrogen**
  2.5–10 mg once daily for 5–10 days during assumed second half of cycle
- **Oral: With estrogen**
  5–10 mg once daily for 10 days.

**Management of Menopausal Symptoms:**  
Refer to [Management of Menopause & Menopausal Symptoms](#)
| Administration | **Oral:**  
|                | Take with or without food  
| **IM:**        | Deep intramuscular injection into the gluteal or deltoid muscle. Shake injection before use.  
| **Pregnancy**  | Medroxyprogesterone acetate (MPA) use during early pregnancy is not associated with an increase in non-genital malformations. There is conflicting evidence on whether hypospadias is associated with MPA use during pregnancy. Theoretically it could cause virilisation of female fetus if taken from 8 weeks after conception although this effect is unlikely as MPA is not a 19-nortestosterone derivative. This is a dose-dependent effect. Prior to 8 weeks post conception, they have no virilising effects  
|               | **IM (contraceptive dose) and Oral < 30mg daily:**  
|               | 1<sup>st</sup> Trimester: Considered safe to use  
|               | 2<sup>nd</sup> Trimester: Considered safe to use  
|               | 3<sup>rd</sup> Trimester: Considered safe to use  
|               | **IM High dose and Oral > 30mg daily:**  
|               | Seek more information from KEMH Obstetric Medicines Information Service.  
| **Breastfeeding** | Considered safe to use  
| **Monitoring** | Refer to clinical practice guidelines  
| **Clinical Guidelines and Policies** | KEMH Clinical Guidelines:  
|               | Contraception: Post-Partum  
|               | Contraception: Depot Medroxyprogesterone Acetate (DMPA)  
|               | SHQ Contraception Injection Information for Patients  
|               | Menopause & menopausal symptoms  
|               | Gynaecology (Non-oncological): Endometriosis quick reference guide  
|               | Menstrual bleeding: Heavy  
|               | KEMH Pharmaceutical & Medicines Management Guidelines:  
|               | KEMH Pharmaceutical & Medicines Management Guideline: Medication Administration  
Medroxyprogesterone - Adult

27]. Available from: https://amhonline.amh.net.au/


https://www.tga.gov.au/node/4012


<table>
<thead>
<tr>
<th>Keywords:</th>
<th>Medroxyprogesterone, Menopause, Contraception, Menstrual Disorder, HRT, Depo Ralovera, Depo Provera, DMPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Publishing:</td>
<td>☒ Intranet ☐ Internet</td>
</tr>
<tr>
<td>Document owner:</td>
<td>Chief Pharmacist</td>
</tr>
<tr>
<td>Author / Reviewer:</td>
<td>KEMH Pharmacy Department</td>
</tr>
<tr>
<td>Date first issued:</td>
<td>March 2015</td>
</tr>
<tr>
<td>Last reviewed:</td>
<td>July 2020</td>
</tr>
<tr>
<td>Endorsed by:</td>
<td>Medicines and Therapeutics Committee</td>
</tr>
<tr>
<td>Standards Applicable:</td>
<td>NSQHS Standards: 1 Governance, 4 Medication Safety</td>
</tr>
</tbody>
</table>

Printed or personally saved electronic copies of this document are considered uncontrolled.
Access the current version from the WNHS website.
For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2020